{"id":"NCT00091793","sponsor":"Amgen","briefTitle":"Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis","officialTitle":"A Randomized, Double-Blind Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-08","primaryCompletion":"2009-02","completion":"2009-03","firstPosted":"2004-09-21","resultsPosted":"2010-01-26","lastUpdate":"2010-12-31"},"enrollment":332,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Postmenopausal Osteoporosis"],"interventions":[{"type":"DRUG","name":"AMG 162","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AMG 162","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.","primaryOutcome":{"measure":"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","timeFrame":"24 Months","effectByArm":[{"arm":"Denosumab 60 mg Q6M","deltaMin":6.5,"sd":null},{"arm":"Placebo","deltaMin":-0.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18381571","19345291","21289258"],"seeAlso":["http://www.amgentrials.com","http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":165},"commonTop":["Arthralgia","Nasopharyngitis","Back pain","Headache","Pain in extremity"]}}